Gene test shows which bladder cancer patients may have cancer spread

Jan 20, 2011

Cancer scientists have designed the first molecular test to predict which bladder cancer patients may have cancer involvement in their lymph nodes at the time of surgery—which could help doctors determine which patients are good candidates for pre-surgical, or neo-adjuvant, chemotherapy.

The test analyzes 20 genes on tumor biopsies, according to a paper published online Jan. 20, 2011, in Lancet Oncology.

"Randomized clinical trials have shown that giving neo-adjuvant chemotherapy extends patient lives, but only 5 to 15 percent of patients benefit," says urologic surgeon Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and lead author of the study. "Patients who have cancer in the lymph nodes at time of diagnosis are likely to benefit the most."

The study analyzed patient tumor samples from the United States, Canada and Germany. It was funded by the National Cancer Institute.

"Today, only about 2 percent of people with invasive bladder cancer have pre-surgical chemotherapy because it's quite difficult to get through and there is fear of delaying surgery," Theodorescu says. "We need a better way to predict who will benefit, and that's what this test does by identifying patients with a high likelihood of lymph node involvement before surgery."

By the time a third of people are diagnosed, bladder cancer has invaded from the bladder lining into the bladder muscle. Gold-standard treatment includes surgical removal of the bladder and the surrounding lymph nodes; some people also undergo radiation treatment. Even with these treatments, the cancer will recur and spread in about half the people—which is almost always fatal.

is diagnosed during a procedure called a transurethral resection—essentially a biopsy of the bladder. Using the new test, pathologists can determine the levels for the 20 genes in the diagnostic tissue sample and indicate whether the patient has cancer in the .

"We validated the test's ability to predict lymph node spread of the cancer in a large sample of patients from a randomized trial," said Theodorescu. "The predictive ability held up. If this new test is used to guide neo-adjuvant chemotherapy, we hope it will both help people with positive nodes live longer and keep people with negative nodes from being overtreated."

A clinical trial of using the test as a treatment guide is being planned.

Explore further: No increased risk of second cancers with radiotx in pelvic CA

Provided by University of Colorado Denver

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Biomarker predicts disease recurrence in colorectal cancer

Feb 17, 2009

Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurr ...

Recommended for you

Scientists zero in on how lung cancer spreads

Dec 24, 2014

Cancer Research UK scientists have taken microscopic images revealing that the protein ties tethering cells together are severed in lung cancer cells - meaning they can break loose and spread, according to ...

Scientists identify rare cancer's genetic pathways

Dec 24, 2014

An international research team, including four Simon Fraser University scientists, has identified the "mutational landscape" of intrahepatic cholangiocarcinoma (ICC), a rare, highly fatal form of liver cancer that disproportionately ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.